Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Tolerability of BIA 6-512 with Levodopa in Healthy Volunteers
NCT03091868Phase 1Completed
- Sponsor
- BIAL
- Start
- Nov 2004
- Primary completion
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of resveratrol in Parkinson's disease (PD) (4 arms), sponsored by BIAL. Primary endpoints: Maximum observed plasma drug concentration at Day 2, Time at which the Cmax occurred at Day 2 and 4 more. Started Nov 2004; status: completed.
02
Drugs
resveratrol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03091868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03091868.